These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 11173316)

  • 1. Dofetilide: a new class III antiarrhythmic agent.
    Al-Dashti R; Sami M
    Can J Cardiol; 2001 Jan; 17(1):63-7. PubMed ID: 11173316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dofetilide, a new class III antiarrhythmic agent.
    Lenz TL; Hilleman DE
    Pharmacotherapy; 2000 Jul; 20(7):776-86. PubMed ID: 10907968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H; Saliba W
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
    N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS; Mauro VF
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI
    Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
    Falk RH; Pollak A; Singh SN; Friedrich T
    J Am Coll Cardiol; 1997 Feb; 29(2):385-90. PubMed ID: 9014993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
    Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
    Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C; Brendorp B; Køber L
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A; Vichiendilokkul A; Racine E; Milad A
    Am J Health Syst Pharm; 2001 Nov; 58(21):2050-9. PubMed ID: 11715827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic effect of the Ca
    Kirchhoff JE; Diness JG; Abildgaard L; Sheykhzade M; Grunnet M; Jespersen T
    Pflugers Arch; 2016 Nov; 468(11-12):1853-1863. PubMed ID: 27722784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
    Jaiswal A; Goldbarg S
    Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.
    Pedersen HS; Elming H; Seibaek M; Burchardt H; Brendorp B; Torp-Pedersen C; Køber L;
    Am J Cardiol; 2007 Sep; 100(5):876-80. PubMed ID: 17719337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.